Novo Nordisk (NVO) Earnings Analysis
Novo Nordisk (NVO) has no confirmed upcoming earnings date. Last quarter (2025-02-05) it beat with EPS 0.91 USD vs 0.88 USD est (+3.4%). It has beaten estimates in 1/1 recent quarters (100%). Trailing P/E 11.33.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NVO next report earnings?
No confirmed upcoming earnings date is currently scheduled for NVO. This page updates as the calendar is published.
NVO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-02-05 | 0.91 USD | 0.88 USD | +3.4% | Beat |
Beat rate: 1/1 (100%) over reported quarters with consensus data.
NVO valuation and analyst view
| Trailing P/E | 11.33 |
|---|---|
| Trailing EPS | 27.452 USD |
| Price / book | 6.80 |
| Dividend yield | 3.76% |
| Market cap | 214.97B |
| Analyst consensus | Buy (23 buy / 13 hold / 3 sell) |
| Avg price target | 52.1 USD |
Related research pages
Frequently asked questions
When is Novo Nordisk (NVO)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for NVO. This page updates as the calendar is published.
Did NVO beat earnings last quarter?
In its 2025-02-05 report, NVO posted EPS of 0.91 USD versus a 0.88 USD estimate — a beat of 3.4%.
What is NVO's earnings track record?
Over the last 1 reported quarters with consensus data, NVO beat estimates 1 times (100%).
What is NVO's current P/E ratio and EPS?
NVO trades at a trailing P/E of 11.33 on trailing EPS of 27.452069681711578 USD.
What do analysts rate NVO?
Analyst consensus is "Buy" across 39 ratings (1 strong buy, 22 buy, 13 hold, 3 sell, 0 strong sell). Average 12-month price target: 52.1 USD.